Session » RA – Diagnosis, Manifestations, & Outcomes Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0492

A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation

10:30AM-12:30PM: Abstract Number: 0498

ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 0493

An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs

10:30AM-12:30PM: Abstract Number: 0474

Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 0488

Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0486

Associations Between Frailty and Incident Cancer and Cancer-related Mortality in Veterans with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0476

Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients

10:30AM-12:30PM: Abstract Number: 0485

Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort

10:30AM-12:30PM: Abstract Number: 0480

Can’t Sleep, Won’t Sleep: A Systematic Review and Meta-Analysis of Insomnia Prevalence in 70,105 Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 0460

Cartilage Damage or (sub)luxation of Finger Joints: Impact on Physical Function in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0462

Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0484

Cluster Analysis Based on Joint Characteristics: A Study of Joint Involvement Profiles in Early Rheumatoid Arthritis (ERA) Patients in China

10:30AM-12:30PM: Abstract Number: 0461

Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0479

Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0495

Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients

10:30AM-12:30PM: Abstract Number: 0481

Differential Effect of Comorbidities on the Clinical Evolution of Early Arthritis by Sex

10:30AM-12:30PM: Abstract Number: 0496

Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints

10:30AM-12:30PM: Abstract Number: 0482

Endothelial Dysfunction and QRISK3 in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0463

Evaluation of Inflammatory Indices as Predictive Biomarkers of Carotid Plaque in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0473

Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology

10:30AM-12:30PM: Abstract Number: 0472

Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis

10:30AM-12:30PM: Abstract Number: 0490

Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality

10:30AM-12:30PM: Abstract Number: 0464

Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

10:30AM-12:30PM: Abstract Number: 0466

Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample

10:30AM-12:30PM: Abstract Number: 0458

Long-Term Outcomes in Seronegative Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0467

Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort

10:30AM-12:30PM: Abstract Number: 0457

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0470

New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers

10:30AM-12:30PM: Abstract Number: 0483

Obesity, Prednisone Use, and Patient-Reported Outcomes Are Predictors of Becoming Difficult-to-Treat in an RA Population Treated with a First-Line Biologic DMARD

10:30AM-12:30PM: Abstract Number: 0499

PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment

10:30AM-12:30PM: Abstract Number: 0468

Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks

10:30AM-12:30PM: Abstract Number: 0497

Relationship Between the Complement System and Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0475

Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort

10:30AM-12:30PM: Abstract Number: 0469

SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound

10:30AM-12:30PM: Abstract Number: 0478

Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity

10:30AM-12:30PM: Abstract Number: 0491

Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0477

The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 0487

The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0465

Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays

10:30AM-12:30PM: Abstract Number: 0459

Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo

10:30AM-12:30PM: Abstract Number: 0471

Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0489

Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0456

Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 0494

Usefulness of the Neutrophil-to-Lymphocyte Ratio, the Platelet-to-Lymphocyte Ratio and the Systemic Immune Inflammatory Index in Assessing Disease Activity in Rheumatoid Arthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].